
Agreement facilitates differentiated ADC targeting Tissue Factor
Adcendo and Multitude Therapeutics have signed a licensing agreement for the development of a novel, highly differentiated antibody-drug conjugate (ADC) targeting Tissue Factor (TF) with the development code ADCE-T02. TF is a clinically validated ADC target that is highly expressed in indications such as non-small cell lung cancer,… Read More
